SCHEMBL6323377

SCHEMBL6323377

COC(=O)CCc1nc(C2CCCN(C(=O)OC(C)(C)C)C2)no1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.44
KDM4E B2RXH2 1/20 0.44
GLA P06280 1/20 0.44
HPGD P15428 1/20 0.44
RECQL P46063 1/20 0.44
HSD17B10 Q99714 1/20 0.44
MIF P14174 1/20 0.42
HDAC4 P56524 2/20 0.41
HDAC6 Q9UBN7 2/20 0.41
TRPV3 Q8NET8 1/20 0.40
USP30 Q70CQ3 3/20 0.40
GLS O94925 2/20 0.40
MAPT P10636 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
JAK2 O60674 1/20 0.39
JAK1 P23458 1/20 0.39
GPR119 Q8TDV5 1/20 0.38
HPGDS O60760 1/20 0.37
LDHA P00338 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6328194 0.90 ALDH1A1 (0.42) ALDH1A1KDM4EGLAHPGDRECQL
SCHEMBL6332208 0.89 MIF (0.44) ALDH1A1KDM4ERECQLMIFHDAC4
SCHEMBL6328098 0.84 ALDH1A1 (0.44) ALDH1A1GLAMIFUSP30MAPT
SCHEMBL6431964 0.83 MIF (0.42) ALDH1A1HPGDMIFMAPTLDHA
SCHEMBL6326083 0.81 MIF (0.41) ALDH1A1MIFMEN1KMT2A
SCHEMBL13678714 0.80 HDAC4 (0.46) ALDH1A1KDM4EGLAHPGDRECQL
SCHEMBL4226907 0.79 HSD11B1 (0.48) ALDH1A1KDM4EGLAHPGDRECQL
SCHEMBL6323599 0.78 GPR119 (0.46) KDM4ERECQLMIFUSP30MAPT
SCHEMBL3137640 0.78 CNR1 (0.46) HDAC4HDAC6TRPV3USP30MEN1
SCHEMBL3137633 0.78 CNR1 (0.46) HDAC4HDAC6TRPV3USP30MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1423120-A4 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF ICOS CORP (US) 2005-12-28 EP disclosed
US-6924284-B2 PARP inhibitors ICOS CORPORATION (US) 2005-08-02 US disclosed
CN-1568187-A 2H-2,3-dinitrogen phenodiazine-1-ketone and using method thereof ICOS CORP (US) 2005-01-19 CN disclosed
EP-1423120-A1 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF ICOS CORPORATION (US) 2004-06-02 EP disclosed
US-20040087588-A1 Parp inhibitors ICOS CORPORATION 2004-05-06 US disclosed
WO-2003015785-A1 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF ICOS CORPORATION (US) 2003-02-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040087588-A1 Parp inhibitors PARP1, PARP2, PARP11 ALDH1A1 338/4885KDM4E 360/4885GLA 1777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.